REPLIGEN CORP (RGEN)

US7599161095 - Common Stock

196.52  +3.12 (+1.61%)

After market: 196.52 0 (0%)

News Image
3 days ago - Repligen Corporation

Repligen Reports Fourth Quarter and Full Year 2023 Financial Results

Reports fourth quarter revenue of $156 million and full year revenue of $639 million Continued strength in orders with fourth quarter book-to-bill ratio of...

News Image
17 days ago - Repligen Corporation

Repligen to Report Fourth Quarter and Full Year 2023 Financial Results

Webcast and Conference Call to Be Held Wednesday, February 21, 2024, at 8:30 a.m. ET...

News Image
a month ago - Seeking Alpha

Danaher stock rises as Sartorius beats in Q4 (NYSE:DHR)

U.S. life sciences toolmakers Danaher (DHR), Repligen (REGN), and Bio-Rad (BIO) see gains as German peer Sartorius (SARTF) posts strong Q4 2023 results. Read more here.

News Image
a month ago - The Motley Fool

How Good Is Your Market Cap Knowledge?

A company with a $50 price per share might have a million shares outstanding or a billion shares outstanding. And unless you know, you don't know the price tag of the stock you're about to buy.

News Image
2 months ago - Repligen Corporation

Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology...

News Image
3 months ago - Seeking Alpha

Repligen to issue $600M convertible senior notes (NASDAQ:RGEN)

Repligen announces $600M convertible senior notes issuance, boosting its year-end cash and cash equivalent guidance to $717M-$727M.

News Image
3 months ago - Repligen Corporation

Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements

WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced that on December 6, 2023, it entered into privately...

News Image
3 months ago - Repligen Corporation

UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report

WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology...

News Image
3 months ago - Repligen Corporation

Repligen Announces Publication of the Company’s 2022 Sustainability Report

WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology...

News Image
4 months ago - Repligen Corporation

Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device

- Targeting ADC and Cell & Gene Therapy Customers -...

News Image
4 months ago - InvestorPlace

A New Bull Market Is Coming! 3 Stocks Set to Soar 65% to 132% Higher

Wall Street has high hopes for these stocks to buy for the next bull market. Consider adding them to your portfolio.

News Image
4 months ago - Seeking Alpha

Repligen beats top and bottom line estimates, narrows FY guidance (NASDAQ:RGEN)

Repligen press release (RGEN): Q3 Non-GAAP EPS of $0.23 beats by $0.07. Revenue of $141.2M (-29.6% Y/Y) beats by $0.55M. Orders strengthened with total book-to-

News Image
4 months ago - Repligen Corporation

Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance

Reports total third quarter revenues of $141.2 million, with base business revenues of $140.1 millionOrders strengthened with total book-to-bill ratio of...

News Image
4 months ago - Seeking Alpha

Revvity's disappointing Q3 report weighs on life sciences tool stocks (NYSE:RVTY)

Revvity (RVTY) plunged to a 52-week low, dragging down other life science tool providers, after the company released a disappointing Q3 report and cut its forecast. Read more here.

News Image
4 months ago - Market News Video

Repligen Becomes Oversold (RGEN)

News Image
4 months ago - Seeking Alpha

Danaher stock falls after Q3 results (NYSE:DHR)

Shares of Danaher Corporation (DHR) fell after disappointing investors with its 2023 outlook despite posting better-than-expected Q3 financials. Read more here.

News Image
4 months ago - Seeking Alpha

MAIA stock climbs on positive Phase 2 data for lung cancer therapy (MAIA)

MAIA (MAIA) stock climbed 6% after the company reported positive Phase 2 data for its immunotherapy THIO in treating advanced non-small cell lung cancer. Read more here.